Lavinia Martino

Medicine & Life Sciences

1. Pulmonary Hypertension 100%
2. Sildenafil Citrate 94%
3. Chronic Obstructive Pulmonary Disease 83%
4. Bronchiolitis Obliterans 69%
5. Lung Compliance 65%
6. Multicenter Studies 65%
7. Pulmonary Arterial Hypertension 59%
8. Randomized Controlled Trials 50%
9. Epigenomics 43%
10. Cardiac Catheterization 43%
11. Placebos 42%
12. Vascular Resistance 41%
13. Hemodynamics 39%
14. Malassezia 35%
15. Lung 34%
16. Transplants 32%
17. Organ Transplantation 27%
18. Partial Pressure 24%
19. Transplant Recipients 23%
20. Lung Diseases 22%
21. Interstitial Lung Diseases 20%
22. Pneumonia 20%
23. Pulmonary Artery 20%
24. Pulmonary Gas Exchange 18%
25. Chronic Disease 18%
26. Survival 18%
27. Quality of Life 17%
28. Phosphodiesterase 5 Inhibitors 17%
29. Histone Methyltransferases 17%
30. Walk Test 16%
31. Therapeutics 15%
32. 5,10-dihydro-5-methylphenazine 15%
33. Oxygen 14%
34. Histone Deacetylases 14%
35. Lung Transplantation 14%
36. Myofibroblasts 14%
37. Histone Code 14%
38. Pressure 14%
39. Untranslated RNA 14%
40. Mycoses 12%
41. Dyspnea 12%
42. Mesenchymal Stem Cells 11%
43. MicroRNAs 10%
44. Histology 9%
45. Body Mass Index 9%
46. Systemic Scleroderma 9%
47. Lung Volume Measurements 9%
48. Exercise 8%
49. Confidence Intervals 8%
50. Mortality 7%